Last updated on May 2018

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Brief description of study

There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation AF following percutaneous intervention PCI with stenting. This study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vitamin K antagonist VKA-based antithrombotic regimen in subjects with AF following PCI with stent placement. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Clinical Study Identifier: NCT02866175

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Virga Jesse Jessa hospital
Hasselt, Belgium
  Connect »